02595.HK_Providing professional financial news and data related to 02595.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies

Tags：

GENFLEET-B 02595.HK Clinical Trial

2026-08-20

GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment

Tags：

GENFLEET-B 02595.HK R&D Progress

2026-08-10

GENFLEET-B (02595.HK) plans to issue in total 13.6 million shares by placement, with estimated net proceeds of HKD 466.9 million

Tags：

GENFLEET-B 02595.HK share placement

2026-07-15

GenFleet Therapeutics (02595.HK) Proposes Placing of 13.6 Million New H-shares at HK$34.69 Per Share

Tags：

GenFleet Therapeutics 02595.HK

2026-07-15

GENFLEET-B(02595.HK) closed 9.28% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends

Tags：

GENFLEET-B 02595.HK

2026-04-24

NewTimeSpace | Breakthrough Designation for New Targeted Drug; GenFleet Therapeutics (02595.HK) Faces Commercialization Pressure Amid Heavy Book Losses

Tags：

02595.HK GenFleet Therapeutics NewTimeSpace

2026-04-10

Scan QR Code

Download App